Abstracts tagged "Systemic JIA and canakinumab"

Abstract Number: 2374 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva⁴, Rayfel Schneider¹, Isabelle Kone-Paut², Kenneth Schikler¹, Katherine Marzan¹, Nico Wulffraat⁴, Shai Padeh⁴, Vyacheslav Chasnyk², Carine Wouters⁴, Jasmin B. Kuemmerle-Deschner⁴, Tilmann Kallinich⁴, Bernard Lauwerys⁵, Elie Haddad¹, Evgeny L Nasonov⁴, Maria Trachana⁴, Olga Vougiouka⁴, Karolynn Leon⁶, Antonio Speziale⁷, Karine Lheritier⁷, Eleni Vritzali⁸, Daniel J Lovell¹, Alberto Martini² and PRINTO/PRCSG, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Hôpital Necker-Enfants Malades, Paris, France, ⁴PRINTO-Istituto Gaslini, Genova, Italy, ⁵Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a highly selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic…
Abstract Number: 3007 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin⁴, Ekaterina Alexeeva⁵, Isabelle Koné-Paut⁶, Katherine Marzan⁷, Nico Wulffraat⁵, Rayfel Schneider⁷, Shai Padeh⁵, Vyacheslav Chasnyk⁸, Carine Wouters⁵, Jasmin B. Kuemmerle-Deschner⁵, Tilmann Kallinich⁵, Bernard Lauwerys⁹, Elie Haddad⁷, Evgeny L Nasonov⁵, Maria Trachana⁵, Olga Vougiouka⁵, Karolynn Leon¹⁰, Eleni Vritzali¹¹, Karine Lheritier¹², Alberto Martini⁵ and Daniel J Lovell¹³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ³Hôpital Necker-Enfants Malades, Paris, France, ⁴Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁵PRINTO-Istituto Gaslini, Genova, Italy, ⁶Pediatric Rheumatology, Department of Paediatric Rheumatology, AP-HP Bicêtre Hospital, Le Kremlin Bicêtre, France, ⁷PRCSG, Cincinnati, OH, ⁸PRINTO-Istituto Gaslini, Genoa, Italy, ⁹Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharma AG, Basel, Switzerland, ¹³Rheumatology, PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN)…
Abstract Number: 2295 • 2014 ACR/ARHP Annual Meeting
A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients
Micha Levi¹, Thomas Dumortier², Nicolino Ruperto³, Hermine H. Brunner⁴ and Olivier Luttringer², ¹Novartis Pharmaceutical Corporation, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose Canakinumab (CAN), a human, selective anti-interleukin-1β monoclonal antibody, has demonstrated rapid and sustained efficacy in systemic juvenile idiopathic arthritis (SJIA) patients,1and is approved in…
Abstract Number: 2298 • 2014 ACR/ARHP Annual Meeting
Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data
A. Ravelli¹, H.I. Brunner², N. Ruperto¹, P. Quartier³, A. Consolaro¹, N.M. Wulffraat⁴, K. Lheritier⁵, C. Gaillez⁵, A. Martini¹ and D.J. Lovell², ¹Istituto Gaslini-PRINTO, Genova, Italy, ²PRCSG, Cincinnati, OH, ³Necker-Enfant Malades Hospital, Paris, France, ⁴UMC Utrecht, Utrecht, Netherlands, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose Key objectives of biologic therapies in systemic juvenile idiopathic arthritis (SJIA) are to induce and maintain inactive disease, according to the ACR 2011 definition.…
Abstract Number: 930 • 2014 ACR/ARHP Annual Meeting
An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Isabelle Koné-Paut², Bo Magnusson², Seza Ozen², Flavio Sztajnbok², Jordi Anton², Judith Barash², Reinhard Berner², Fabrizia Corona², Karine Lheritier³, Corine Gaillez³, Alberto Martini² and Daniel Lovell¹, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose Systemic juvenile idiopathic arthritis (SJIA), an interleukin-1β (IL-1β)-mediated autoinflammatory disease, is characterized by recurrent flares of active disease. Canakinumab (CAN), a selective, human, anti-…
Abstract Number: 2029 • 2013 ACR/ARHP Annual Meeting
Exposure-Response Modeling Of Canakinumab In The Avoidance Of Flares In Children With Systemic Juvenile Idiopathic Arthritis
Yuan Xiong¹, Wenping Wang¹, William Ebling¹, Haiying Sun¹, Olivier Luttringer², Ken Abrams¹, Nicola Ruperto³ and Hermine Brunner⁴, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Istituto Gaslini, Genova, Italy, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Canakinumab (CAN), a fully human selective anti-IL-1β monoclonal antibody, has been shown to be efficacious in systemic juvenile idiopathic arthritis (SJIA), resulting in significantly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].